See the DrugPatentWatch profile for aristada
What Is Aristada Used For?
Aristada (aripiprazole lauroxil) is an injectable antipsychotic medication approved for treating schizophrenia in adults. It helps manage symptoms like hallucinations, delusions, and disorganized thinking by balancing dopamine and serotonin levels in the brain.[1]
How Does Aristada Fit Into Mental Health Treatment?
Schizophrenia is a chronic mental disorder, so yes, Aristada is specifically for mental health. It's a long-acting form given every 4-8 weeks via intramuscular injection, designed for patients who struggle with daily oral meds. The FDA approved it in 2015 for maintenance treatment after initial stabilization.[1][2]
Who Typically Gets Prescribed Aristada?
It's for adults 18+ with schizophrenia. Not approved for bipolar disorder, depression, or other conditions like Aristada Initio (a shorter-acting version for initiation). Doctors use it when adherence is an issue, reducing relapse risk compared to pills.[2]
What Are Common Side Effects and Risks?
Patients report weight gain, drowsiness, akathisia (restlessness), and injection-site pain. Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, and high blood sugar. Long-term use requires monitoring; it's not for everyone due to these.[1][3]
How Does Aristada Compare to Other Antipsychotics?
Unlike daily orals like Abilify (aripiprazole), Aristada lasts a month per dose. Vs. Invega Sustenna (paliperidone), it has similar efficacy but different release mechanisms. No head-to-head trials show clear superiority; choice depends on side effects and patient needs.[2]
When Does the Aristada Patent Expire?
Key U.S. patents on Aristada expire between 2030 and 2033, per DrugPatentWatch data. Alkermes holds formulation patents; generics unlikely before then without challenges.[4]
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207485lbl.pdf
[2]: Alkermes Prescribing Information - https://www.aristada.com/
[3]: Mayo Clinic - https://www.mayoclinic.org/drugs-supplements/aripiprazole-lauroxil-subcutaneous-route-intramuscular-route/description/drg-20406207
[4]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/ARISTADA